Immune Checkpoint Inhibitors
| Cat. No. | Product Name / Activity |
|---|---|
| 4392 | 680C91 |
| Potent and selective tryptophan 2,3-dioxygenase (TDO) inhibitor | |
| 7831 | AUNP 12 |
| Peptide inhibitor of the PD-1 signaling pathway | |
| 1545 | (R)-(+)-Bay K 8644 |
| TMEM176B inhibitor; activates inflammasomes; also CaV1.x blocker | |
| 6007 | INCB 024360-analog |
| Potent indoleamine 2,3-dioxygenase (IDO) inhibitor | |
| 6068 | Lin28 1632 |
| Lin28 inhibitor; suppresses PD-L1 expression and enhances T cell-mediated antitumor immunity; also bromodomain inhibitor | |
| 5698 | 1-Methyl-D-tryptophan |
| Indoleamine 2,3-dioxygenase (IDO) inhibitor | |
| 8119 | ML T7 New |
| Inhibitor of phosphatidylserine/CEACAM1 binding to Tim-3 | |
| 6370 | Nor NOHA monoacetate |
| Arginase inhibitor | |
| 6515 | (D)-PPA 1 |
| PD-1/PD-L1 interaction inhibitor | |
| 8050 | SA-15-P New |
| Dual inhibitor of LAG3 interaction with both MHCII and FGL1 | |
| 6979 | SEN 177 |
| Disrupts binding of SIRP-α to CD47; potent glutaminyl cyclase inhibitor. | |
| 7533 | ZE 132 |
| Potent and selective PD-1/PD-L1 interaction inhibitor |
Cancer Metabolism Life Science Poster
Taken from the Cancer Product Guide Edition 3
Our Cancer Metabolism poster summarizes the main metabolic pathways in cancer cells, and highlights potential targets for cancer therapeutics.
Request copyDownload PDF